FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business.

Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases.

The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.

FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.